CHRS Coherus BioSciences Inc.

17.57
-0.73  -4%
Previous Close 18.3
Open 18.18
Price To Book 21.96
Market Cap 1,232,172,504
Shares 70,129,340
Volume 1,486,990
Short Ratio
Av. Daily Volume 1,254,871
Stock charts supplied by TradingView

NewsSee all news

  1. Coherus BioSciences Management to Present at Two Upcoming Investor Healthcare Conferences

    REDWOOD CITY, Calif., Nov. 12, 2019 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (("Coherus", NASDAQ:CHRS), today announced that senior management will present at two upcoming investor healthcare conferences.

  2. Coherus BioSciences Announces New Employment Inducement Grants

    REDWOOD CITY, Calif., Nov. 08, 2019 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (("Coherus" or the "Company", NASDAQ:CHRS), today announced that effective November 7, 2019, the compensation committee of the Company's

  3. Coherus Acquires Commercial Rights for Leading Lucentis Biosimilar in the United States

    REDWOOD CITY, Calif., Nov. 06, 2019 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (("Coherus" or the "Company", NASDAQ:CHRS), today announced the Company has acquired exclusive rights from Bioeq IP AG, ("Bioeq") a

  4. Coherus BioSciences Reports Corporate Highlights and Third Quarter 2019 Financial Results

    REDWOOD CITY, Calif., Nov. 06, 2019 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (("Coherus" or the "Company", NASDAQ:CHRS), today reviewed corporate highlights and reported financial results for the quarter ended

  5. Bioeq Announces Coherus as Marketing and Distribution Partner for Its Biosimilar to Lucentis® (ranibizumab) in the U.S.

    ZÜRICH, Nov. 6, 2019 /PRNewswire/ -- Bioeq IP AG ("Bioeq") today announced that it signed a license and development agreement with Coherus BioSciences, Inc. ((", Coherus", NASDAQ:CHRS), under which Coherus

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 3 data released January 2016. Endpoints met. However, commercialization not possible in US before 2029 due to patent issues
CHS-0214
Rheumatoid arthritis
Phase 2b data released June 2016
CHS-131
Relapsing remitting multiple sclerosis (RRMS)
Phase 3 top-line data met endpoints August 2016. BLA filing due in 2020.
CHS-1420
Psoriasis
Phase 3 trial met endpoint November 2015. However, commercialization not possible in US before 2029 due to patent issues
CHS-0214
Psoriasis
FDA approval announced November 2, 2018.
CHS-1701
Pegfilgrastim biosimilar
BLA filing due 4Q 2019.
Lucentis Biosimilar
Biosimilar

Latest News

  1. Coherus BioSciences Management to Present at Two Upcoming Investor Healthcare Conferences

    REDWOOD CITY, Calif., Nov. 12, 2019 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (("Coherus", NASDAQ:CHRS), today announced that senior management will present at two upcoming investor healthcare conferences.

  2. Coherus BioSciences Announces New Employment Inducement Grants

    REDWOOD CITY, Calif., Nov. 08, 2019 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (("Coherus" or the "Company", NASDAQ:CHRS), today announced that effective November 7, 2019, the compensation committee of the Company's

  3. Coherus Acquires Commercial Rights for Leading Lucentis Biosimilar in the United States

    REDWOOD CITY, Calif., Nov. 06, 2019 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (("Coherus" or the "Company", NASDAQ:CHRS), today announced the Company has acquired exclusive rights from Bioeq IP AG, ("Bioeq") a

  4. Coherus BioSciences Reports Corporate Highlights and Third Quarter 2019 Financial Results

    REDWOOD CITY, Calif., Nov. 06, 2019 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (("Coherus" or the "Company", NASDAQ:CHRS), today reviewed corporate highlights and reported financial results for the quarter ended

  5. Bioeq Announces Coherus as Marketing and Distribution Partner for Its Biosimilar to Lucentis® (ranibizumab) in the U.S.

    ZÜRICH, Nov. 6, 2019 /PRNewswire/ -- Bioeq IP AG ("Bioeq") today announced that it signed a license and development agreement with Coherus BioSciences, Inc. ((", Coherus", NASDAQ:CHRS), under which Coherus

  6. Bioeq Announces Coherus as Marketing and Distribution Partner for Its Biosimilar to Lucentis® (ranibizumab) in the U.S.

    ZÜRICH, Nov. 6, 2019 /CNW/ -- Bioeq IP AG ("Bioeq") today announced that it signed a license and development agreement with Coherus BioSciences, Inc. ((", Coherus", NASDAQ:CHRS), under which Coherus will

  7. Coherus BioSciences Announces New Employment Inducement Grants

    REDWOOD CITY, Calif., Oct. 18, 2019 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (("Coherus" or "the Company", NASDAQ:CHRS), today announced that effective October 17, 2019, the compensation committee of the Company's

  8. Coherus BioSciences to Report Third Quarter Financial Results on November 6th

    REDWOOD CITY, Calif., Oct. 15, 2019 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (("Coherus" or "the Company", NASDAQ:CHRS), today announced that its third quarter 2019 financial results will be released after market

  9. Coherus BioSciences Announces New Employment Inducement Grants

    REDWOOD CITY, Calif., Sept. 20, 2019 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (NASDAQ:CHRS), today announced that effective September 19, 2019, the compensation committee of the company's board of directors

  10. Coherus BioSciences Announces New Employment Inducement Grants

    REDWOOD CITY, Calif., Aug. 22, 2019 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (NASDAQ:CHRS), today announced that effective August 21, 2019, the compensation committee of the company's board of directors granted 13